US · HALO · BIOTECHNOLOGY
Halozyme Therapeutics, Inc. (HALO) intrinsic value and stock valuation
$91.35as of 2026-11-21 · Mkt cap 9.91B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Halozyme Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values HALO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HALO’s statements →
Halozyme Therapeutics, Inc. Graham Number
Graham Number: $4.92d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Jazz Pharmaceuticals plc (JAZZ) $230.26
- Corcept Therapeutics Incorporated (CORT) $63.62
- Henry Schein, Inc. (HSIC) $83.52
- Cytokinetics, Incorporated (CYTK) $50.78
- Abivax S.A. (ABVX) $73.20
- AptarGroup, Inc. (ATR) $140.08
- Rhythm Pharmaceuticals, Inc. (RYTM) $112.36
- Grifols, S.A. (GRFS) $8.15
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.02B | $829.3M | $660.1M | $443.3M |
| Operating income | $816.3M | $551.5M | $337.6M | $267.5M | $275.9M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| EPSd | $2.56M | $3.43M | $2.1M | $1.44M | $2.74M |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Capital expenditure | -$-6.97M | -$-10.7M | -$-15.29M | -$-4.81M | -$-1.46M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298M |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.1B |
| Total debt | $2.14B | $1.51B | $1.5B | $1.51B | $876.7M |
| Net debt | $2.01B | $1.39B | $1.38B | $1.27B | $758M |
| Total equity | $48.8M | $363.8M | $83.8M | $169.8M | $197M |
| Cash and short-term investments | $142.8M | $596.1M | $336M | $362.8M | $740.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.02B | $829.3M | $660.1M | $443.3M |
| Cost of revenue | $305.4M | $159.4M | $192.4M | $139.3M | $81.4M |
| Gross profit | $1.09B | $855.9M | $636.9M | $520.8M | $361.9M |
| Research and development expenses | $81.5M | $79.1M | $76.4M | $66.6M | $35.7M |
| Selling, general and administrative expenses | $193.4M | $154.3M | $149.2M | $143.5M | $50.3M |
| Other expenses | $0.00 | $71.1M | $73.8M | $43.2M | $0.00 |
| Operating expenses | $274.9M | $304.4M | $299.3M | $253.3M | $86M |
| Cost and expenses | $580.3M | $463.9M | $491.7M | $392.6M | $167.4M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $18.1M | $18.1M | $18.8M | $17M | $7.53M |
| Depreciation and amortization | $88.1M | $81.3M | $84.9M | $49.6M | $3M |
| Ebitda | $573.1M | $656.5M | $452M | $315.5M | $259M |
| Operating income | $816.3M | $551.5M | $337.6M | $267.5M | $275.9M |
| Total other income/expenses, net | -$-349.42M | $5.66M | $10.8M | -$-18.61M | -$-27.38M |
| Income before tax | $466.9M | $557.1M | $348.3M | $248.9M | $248.5M |
| Income tax expense | $150M | $113M | $66.7M | $46.8M | -$-154.19M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Weighted average shares outstanding | $119.8M | $126.8M | $131.9M | $136.8M | $140.7M |
| Weighted average diluted shares outstanding | $123.9M | $129.4M | $134.2M | $140.6M | $146.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $142.8M | $596.1M | $336M | $362.8M | $740.9M |
| Net receivables | $441.3M | $308.5M | $234.2M | $231.1M | $91M |
| Inventory | $176.5M | $141.9M | $127.6M | $100.1M | $53.9M |
| Total current assets | $825.2M | $1.09B | $746.4M | $739M | $926.3M |
| Property, plant and equipment, net | $82.1M | $75M | $74.9M | $75.6M | $8.79M |
| Goodwill and intangible assets | $1.56B | $818.7M | $889.7M | $955.7M | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $500K |
| Total non-current assets | $1.7B | $978.1M | $986.9M | $1.1B | $178.1M |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.1B |
| Accounts payable | $20.9M | $10.3M | $11.8M | $17.7M | $1.54M |
| Short-term debt | $0.00 | $0.00 | $0.00 | $13.3M | $89.4M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $3.25M | $1.75M |
| Total current liabilities | $177.1M | $139.1M | $112.5M | $130.8M | $117.2M |
| Long-term debt | $2.14B | $1.51B | $1.5B | $1.49B | $787.3M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $2.25M | $2.53M |
| Total non-current liabilities | $2.3B | $1.56B | $1.54B | $1.54B | $790.3M |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $2.48B | $1.7B | $1.65B | $1.67B | $907.5M |
| Common stock | $120K | $120K | $130K | $140K | $140K |
| Retained earnings | $54.8M | $359.9M | $90.6M | $143.2M | -$-58.91M |
| Accumulated other comprehensive income (loss) | -$-18.09M | $3.83M | -$-9.28M | -$-920K | -$-620K |
| Total equity | $48.8M | $363.8M | $83.8M | $169.8M | $197M |
| Total investments | $9M | $480.2M | $217.6M | $128.6M | $622.7M |
| Total debt | $2.14B | $1.51B | $1.5B | $1.51B | $876.7M |
| Net debt | $2.01B | $1.39B | $1.38B | $1.27B | $758M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| Depreciation and amortization | $88.1M | $88.7M | $84.9M | $57.5M | $6.64M |
| Stock-based compensation | $51.6M | $43.4M | $36.6M | $24.4M | $20.8M |
| Change in working capital | -$-152.26M | -$-136.27M | -$-38.67M | -$-110.49M | $2.57M |
| Accounts receivable | -$-128.06M | -$-74.25M | -$-3.34M | -$-83.94M | $6.75M |
| Inventory | $2.55M | -$-67.38M | -$-26.88M | -$-17.48M | $7.37M |
| Accounts payable | $0.00 | $0.00 | -$-12.55M | $0.00 | $0.00 |
| Net cash provided by operating activities | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Investments in property, plant and equipment | -$-6.97M | -$-10.7M | -$-15.29M | -$-4.81M | -$-1.46M |
| Acquisitions, net | -$-725.97M | $0.00 | $0.00 | -$-999.12M | $0.00 |
| Net cash used for investing activities | -$-545.81M | -$-262.72M | -$-96.91M | -$-487M | -$-406.29M |
| Common stock issued | $21.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-342.37M | -$-250M | -$-402.38M | -$-200M | -$-350.06M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-85.17M | -$-218.86M | -$-407.99M | $362.4M | $77.9M |
| Net change in cash | $20.6M | -$-2.52M | -$-116.33M | $115.5M | -$-28.98M |
| Cash at end of period | $136.4M | $115.9M | $118.4M | $234.7M | $119.2M |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Capital expenditure | -$-6.97M | -$-10.7M | -$-15.29M | -$-4.81M | -$-1.46M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298M |
Line items
Line items
Line items
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
- CEO
- Helen I. Torley
- Employees
- 423
- Beta
- 0.84
Explore
Frequently asked questions
What is the intrinsic value of Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. (HALO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is HALO undervalued?
HALO trades at a price of $91.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.